Therefore, radioligand-based diagnosis and treatment targeting PSMA is not limited to prostate cancer (14), but may also be useful for the screening, targeting, and efficacy monitoring of patients with other anti-angiogenic therapies. The gene discussed is FOLH1; the disease is prostate cancer.